Content area
Background
Recent research in life course epidemiology has demonstrated the importance of evaluating how prepregnancy and pregnancy exposures affect later life developmental outcomes. In this scoping review, we identified and described completed or ongoing pregnancy and prepregnancy cohorts to assess gaps in the maternal exposures and child outcomes measured in these initiatives and inform future research investments.
Methods
We developed a systematic search that included text and MeSH terms and was tailored for four biomedical citation databases. We applied the Arskey and O’Malley scoping review methodology. We selected a scoping review methodology to provide a comprehensive overview of pregnancy and prepregnancy cohorts and their characteristics. Two reviewers independently conducted the title, abstract, full-text screening, and data charting; a third reviewer resolved discrepancies. The results were summarised in narrative form.
Results
We reviewed 147 manuscripts that presented findings from 56 pregnancy and two prepregnancy cohorts, 23 of which were ongoing. Half of the pregnancy cohorts were based in Europe. The most commonly described maternal exposures were nutrition, anthropometric measures, non-communicable diseases (NCDs), and demographic factors. Children’s mental, behavioural, neurodevelopmental, and physical outcomes were the most commonly measured outcomes. Fewer studies evaluated infectious disease, biomarkers, and environmental or workplace exposures. No cohorts examined vaccine or climate-related exposures during pregnancy. About half of the cohorts collected samples from pregnant women or the fetus, and a third from children, with blood being the most common sample type. Most studies did not indicate how data or samples could be accessed.
Conclusions
This comprehensive overview of pregnancy and prepregnancy cohorts provides a foundation for cross-cohort coordination. Infectious disease, vaccine, environmental, and climate-related exposures and microbiome, immune function, and economic outcomes remain underrepresented in pregnancy and prepregnancy cohorts.
Ethics and dissemination
This scoping review summarises findings from existing publications in peer-reviewed journals and did not require ethics review.
Background
Pregnancy and prepregnancy cohorts are essential for understanding the short- and long-term effects of pre- and pregnancy exposures to infectious disease (ID), nutrition, medication, vaccines, illicit drugs, and environmental, behavioural, and socioeconomic exposures. Pregnancy cohorts are longitudinal observational studies that enroll women during pregnancy and follow them through gestation, childbirth, and, in some cases, into the postpartum period and early childhood, tracking maternal exposures during pregnancy and their potential effects on pregnancy outcomes and fetal, infant, and child health. Prepregnancy cohorts recruit participants and begin data collection on various exposures before conception, but otherwise follow a similar design, tracking maternal, fetal, and child outcomes. Pregnant women are underrepresented in or excluded from most clinical trials, which underscores the need for observational data collected during pregnancy to understand the effects of medication or vaccine exposures. Prepregnancy cohorts offer unique insights into how the preconception period affects fetal, infant, and child development, providing information on the potential risks and benefits associated with various exposures.
The importance of prepregnancy and pregnancy cohorts with longer-term follow-up
Many adverse effects of prenatal exposures, including cognitive, behavioral, and neurodevelopmental outcomes, cannot be reliably assessed before two years of age. Key developmental milestones in executive function, language, and social-emotional regulation typically begin to manifest between 18 and 36 months of age and require age-appropriate standardized assessments that are not feasible in neonates or infants [1, 2]. Neurodevelopmental delays associated with exposures such as maternal obesity [3], malnutrition [4, 5], diabetes [6], hypertension [7], and infection [8] often do not present until after the second year of life, when children are more capable of completing structured cognitive and behavioral evaluations. For example, impairments linked to prenatal exposure to Zika virus or cytomegalovirus may include delayed language acquisition, hearing loss, or motor impairment [8], which cannot be detected reliably at birth or during early infancy. Additionally, pregnancy-related exposures are linked to development of mental health issues [9], cancers [10], and other non-communicable diseases (NCDs) that may not develop before two years of age. Cataloguing pregnancy and prepregnancy cohorts that track infants to two years and beyond helps to highlight the available data that can be used to examine such associations further. Below, we briefly describe key maternal exposures and their potential short- and long-term effects on child health, underscoring the importance of prepregnancy and pregnancy cohort studies in advancing our understanding of fetal, infant, and child health.
Nutrition
Maternal nutritional intake can have short and long-term effects on child health and disease risk [5, 11]. Maternal obesity has been linked to perinatal mortality [12], impaired child glucose tolerance [13], and poor cognitive performance [3]. Maternal underweight is related to a higher risk of low birth weight (LBW), under-five mortality, and poor physical and psychological development [14]. Nutrient deficiencies in pregnancy can stunt fetal growth, increasing the likelihood of LBW and small-for-gestational-age (SGA) [11]. Maternal underweight and malnutrition increase the child’s risk of congenital heart disease (CHD) [15] and NCDs [11]. Studies have also related maternal choline and vitamin D deficiency to impaired cognitive development [4, 5]. Given such wide-ranging consequences of maternal nutrition, pregnancy and prepregnancy cohorts provide a critical window to identify nutritional exposures before and during pregnancy, and enable the examination of their effects on maternal and child health (MCH).
Non-communicable diseases
Maternal NCDs, such as obesity, diabetes, hypertension, cardiovascular disease, and autoimmune disorders, can influence fetal development through a number of pathways, increasing the risk of adverse birth outcomes and long-term health complications in the offspring. For example, maternal hypertension was linked to adverse child growth outcomes and a heightened risk of cardiovascular disease (CVD) [16, 17]. Maternal diabetes is associated with higher child body-mass index (BMI) [18, 19], psychiatric disorders [9], and delayed language development [6].
Infectious exposures
Pregnant women with COVID-19 [20, 21], symptomatic dengue [22], malaria [23], Zika virus (ZIKV) [24], syphilis [25], parvovirus B19 [26], rubella [27], cytomegalovirus, and herpes simplex virus (HSV) [28] have a higher risk of neonatal morbidity and mortality. Maternal infections during pregnancy have been related to a higher risk of later life developmental [29], psychological [30,31,32], and physical issues, including cancers [10]. Both ZIKV and rubella infections in pregnancy are related to a spectrum of adverse congenital outcomes, such as cardiac, ocular, and hearing defects [27], as well as neurological abnormalities [33, 34]. ZIKV is also a recognised cause of long-term impairments, such as cerebral palsy and epilepsy [35], while rubella has been associated with later-life conditions, including diabetes, thyroid disease, growth hormone deficiency, and progressive panencephalitis [36]. Malaria [23], HSV [37], CMV [38], and ZIKV [39] infection in pregnancy have been linked to neurodevelopmental issues that are not observable at birth, including neurocognitive and language delays, and later-life hearing loss.
Social exposures
Social determinants, such as socioeconomic position, education, employment, and living environment play a critical role in shaping maternal, fetal and child health. Low socioeconomic status is consistently associated with adverse pregnancy outcomes, particularly low birthweight and preterm birth [40]. In addition to socioeconomic factors, minority race identity has been linked to adverse pregnancy outcomes such as higher rates of morbidity and mortality [41], while exposure to poverty during pregnancy is associated with delayed cognitive development and poor educational outcomes in children [42]. Maternal exposure to intimate partner violence (IPV) has also been linked to poor developmental outcomes, partly through its effect on maternal depression [43, 44]. While this body of evidence continues to grow, interventions to mitigate the effects of social disadvantage remain limited, and few studies evaluate their effectiveness across diverse settings.
Natural disasters or societal crises
Prenatal exposure to disasters may affect child development and physical and mental health through its impact on maternal stress, although a recent systematic review showed conflicting findings, with some studies identifying strong associations – such as between famine and schizophrenia – while others found limited or no effects or showed inconsistent results across similar contexts [45]. Prenatal exposure to famine is associated with children’s risk of CVD, Type 2 diabetes mellitus (T2DM), cancer [46], mental health disorders [47], and reduced quality of life in adulthood [48].
Study approach and objectives
Exposures immediately before or during fetal development are essential determinants of childhood growth and development and the risk for disease later in life [49]. In this scoping review, we systematically identified pregnancy and prepregnancy cohorts that followed children to at least two years of age to understand what populations, exposures, outcomes, and samples were included in these studies. We restricted our review to pregnancy and prepregnancy cohorts that followed children for at least two years to ensure inclusion of studies capable of capturing developmental outcomes that only emerge beyond infancy. Additionally, while there are many more cohorts that follow pregnant women to birth or until their infants are under age two, the magnitude of infrastructure, personnel, data, and biospecimen collection resources required to sustain longitudinal follow-up beyond two years is substantially greater than that needed for studies limited to birth outcomes or early infant development. Cohorts with extended follow-up provide rich insights into life course epidemiology and longitudinal causal inference [49]. By focusing on cohorts with follow-up of at least two years, our review prioritizes initiatives with the scope and scale necessary to examine how prepregnancy and maternal exposures influence long-term child development.
Information on data and biospecimen collection and availability can help researchers better utilise existing resources to understand the relation between maternal exposures and child physical and developmental outcomes. We also summarised information on pregnancy and prepregnancy cohort data sharing and registries and platforms to help researchers understand how cohort datasets and samples are made available for reuse.
Unlike systematic reviews, which focus on synthesizing findings from studies to answer a specific research question, scoping reviews aim to explore the existing literature and map the breadth of available research to help identify more specific subject areas for a subsequent systematic review. We chose a scoping review approach because we were interested in describing the ecosystem of pre- and pregnancy cohorts rather than summarising the findings of individual studies. Review questions were developed through consultation with the research team and feedback from biomedical researchers who work with pregnancy and prepregnancy cohorts in the context of ID and NCDs. Key review questions included:
1. 1.
What pregnancy and prepregnancy cohorts exist that follow infants to two years of age and beyond?
2. 2.
What exposures do they measure before or during pregnancy?
3. 3.
What maternal, fetal, infant, child, or adult outcomes do they measure?
4. 4.
What samples do they collect from pregnant women, their partners, the fetus, the infant, or the child?
5. 5.
Do they share participant-level data and samples from their cohort? Where? What mechanisms are in place to facilitate access to that data?
Methods
We used the Arksey and O’Malley approach to scoping reviews [50] and presented results per the PRISMA Extension for Scoping Reviews guidance (PRISMA-ScR) [51]. The detailed PRISMA-ScR checklist is provided in Additional File 1. The protocol and systematic search strategy were published on F1000 before initiating the search [52].
Data sources, search strategy, & eligibility criteria
We searched the following databases from 1 January 2000 to 19 February 2021: Ovid (Medline), Ovid (EMBASE), Web of Science, and LILACs. The search strategies (Additional File 2) included a combination of text and MeSH terms tailored for each database and were developed in consultation with an information scientist at the University of Colorado. We did not limit the search by geography or language. We included prospective, primary research studies that reported on pregnancy or prepregnancy cohorts and followed infants for more than two years after birth because of the importance of studying the impact of pre and pregnancy exposures on longer-term development. Prepregnancy cohorts were defined as cohorts that enrolled women and collected data before conception. We excluded retrospective cohorts limited to data from previously collected medical records or national registries that did not prospectively enroll participants before or during pregnancy. Cohorts that prospectively enrolled women prior to or during pregnancy that also included data from previously collected EHR were included. We excluded RCTs, commentaries, editorials, systematic or scoping reviews, non-peer-reviewed research, and non-pregnancy-focused longitudinal studies that did not assess pregnancy exposures and child outcomes.
Title abstract, full-text screening, and data extraction
Citations were exported to EndNote X9 for deduplication. Two reviewers screened all titles, abstracts, and full texts. Disagreements during the title-abstract and full-text screening were resolved through discussion with a third reviewer. A list of studies excluded at the full-text review stage and reasons for exclusion is provided in Additional File 3. We developed and piloted a data extraction and charting form (Additional File 4) to facilitate the descriptive synthesis of our findings before beginning the charting process. Two reviewers independently completed data extraction and charting using COVIDENCE systematic review software [53]. At the beginning of the data extraction process, the two reviewers reviewed one another’s work to ensure consistent interpretation of data extraction and charting items. After a satisfactory level of agreement was achieved in the first three studies, they independently extracted data and reviewed any differences in the interpretation of the data after extraction was finalized for the remaining studies. Where studies presented data from the same cohorts, we summarised the results at the cohort level. To ensure the comprehensiveness of the reporting information, we first collected information related to cohorts from the manuscripts and then we searched Google Scholar and the manuscript citation lists for related publications and, if available, cohort websites that further detailed overall cohort characteristics. We did not use reference lists of publications to identify new cohorts, i.e., we did not conduct snowball sampling, but rather to gather more information on cohorts already included.
We extracted data on the study objectives, location of recruitment, dates of enrollment, funding sources, overall aim(s) stated by cohorts, types of exposures measured in women during or before pregnancy (e.g., demographic factors, infectious exposures, social exposures); pregnancy, infant, and child outcomes measured by the cohorts (e.g., biological, social, and cognitive measures); and types of maternal, infant, and child samples collected and made available by cohorts (e.g., sample type, frequency, storage, and accessibility). Where studies reported a range of follow-up times (e.g., 31–46 months of follow-up), we used the upper limit to calculate the mean follow-up time, because the upper limit reflected the intended follow-up period planned by the cohort, while the lower limit often represented dropouts or incomplete follow-ups. Lastly, we conducted a grey literature search for platforms or repositories that harmonise and disseminate or otherwise host participant-level data and study-level metadata across prepregnancy and pregnancy cohorts. We included platforms or registries if they provided access to individual participant-level data or metadata from multiple prepregnancy or pregnancy cohorts and were publicly accessible or described in peer-reviewed or grey literature sources. The results of the data charting process are presented in narrative form to identify patterns across cohorts in populations, structure, and the range of exposures, outcomes, biospecimens, and data-sharing practices examined in the review. As our objective was to summarize the landscape of existing pregnancy and prepregnancy cohorts, we did not review study quality. Since scoping reviews are intended to provide a broad overview of the scientific literature rather than evidence related to the findings of included studies, scoping reviews generally do not assess study quality [50, 54, 55].
Results
The systematic search results are presented in the Fig. 1 PRISMA flow diagram. After deduplication, we identified 8,068 citations that were screened for inclusion. We evaluated 357 full texts and extracted data from the 147 manuscripts that met our inclusion criteria. Studies were most commonly excluded due to wrong study design (e.g., reliance on national registries, electronic health records, RCTs, non-peer-reviewed publications, or systematic reviews), wrong patient population (e.g., cohorts not focused on pregnant women or women of reproductive age), wrong outcomes (e.g., studies not measuring birth or child outcomes), or pregnancy cohorts with fewer than two years of follow-up.
[IMAGE OMITTED: SEE PDF]
Table 1 provides an overview of the included pregnancy and prepregnancy cohorts. We identified three cohort profiles that provided general information about the cohorts, including overall aims, cohort setup, recruitment and eligibility criteria, types of data and samples collected, and study findings. The other 144 manuscripts were primary research articles investigating the effects of various prenatal exposures on child outcomes. These studies presented data from 56 cohorts in 26 countries. Two cohorts enrolled women before pregnancy [56, 57], and the other 54 enrolled pregnant women. We identified two pregnancy cohorts in Africa, four in Asia, five in Central and South America, seven in Oceania, 13 in North America, and 23 in Europe. One prepregnancy cohort was in Singapore [57], and the other recruited women in Mexico [56]. Five cohorts were limited to special populations, including farmworkers in California [58], Australian indigenous women [59], Australian women exposed to the 2011 Queensland floods [60], women with low household incomes [61], and adolescents aged 13 to 19 [62]. The number of participants enrolled in each cohort varied considerably, from 53 to 101,042 women (mean = 6,992) and 53 to 92,670 children (mean = 8,384). The Danish National Birth Cohort (DNBC) [63] and the Norwegian Mother and Child Cohort (MoBa) [64], which recruited over 95,000 women to participate from Denmark and Norway, respectively, were the largest cohorts. A few cohorts did not provide information on the number of women enrolled and children followed. When manuscripts, cohort profiles, or cohort websites did not explicitly state that the cohort was ongoing or that further follow-ups were planned, we considered them as having completed data collection.
[IMAGE OMITTED: SEE PDF]
Because the focus of this review was on the design and focus of prepregnancy and pregnancy cohorts, we did not collect data on how many participants in each cohort did not complete follow-up or missed certain time points. Cohorts that had stopped collecting data followed infants and children between 36 months and 26 years of age (mean = 7.3 years).
The number of follow-ups ranged from one to over 60 (mean = 6.3). We identified 28 cohorts that were ongoing at the time of data extraction. Of those, children were followed between 4 years of age and adulthood, including several cohorts that followed children from more than 30 years. The DNBC [63] recruited its first participant in 1995, and the MoBa cohort [64] in 1999. Both these cohorts were ongoing at the time of data extraction, having followed children into young adulthood. The Mater-University of Queensland Study of Pregnancy (MUSP) [65], the Healthy Habits for Two cohorts [66], the Western Australian Pregnancy Cohort Study (Raine) [67], the Seychelles Child Development Study [68], the Early Determinant of Mammographic Density Study [69], and the European Longitudinal Study of Pregnancy and Childhood (ELSPAC) [70] were the longest-running cohorts with a follow-up period of over 30 years each. The frequency of follow-ups varied greatly. Generally, infants were followed up multiple times yearly in their first one to three years. Following infancy, the frequency of follow-up ranged from annually to once every five years. We could not assess the follow-up schedule for children over 18 in the Healthy Habits for Two cohort [66].
Cohorts generally had broadly defined aims and explored multiple prenatal exposures and fetal, infant, and child outcomes. Most cohorts with more focused aims assessed the relationship between maternal nutrition and child cognitive development, maternal environmental exposures and child development [58, 71, 72], maternal psychological disorders and child cognitive outcomes [73], maternal racial and ethnic differences and child health, and the effects of intergenerational trauma [74] and stress related to environmental disasters [60]. Additional File 5 presents cohort aims, and Additional File 6 provides an overview of the types of maternal exposures measured across pregnancy and prepregnancy cohorts. The spider plots in Figs. 2 and 3 show how many pregnancy and prepregnancy cohorts measured different categories of maternal exposures and child outcomes. Most cohorts collected data on maternal anthropometric measures, sociodemographic factors, nutrition, and pregnancy outcomes, while relatively few assessed STORCH (Syphilis, Toxoplasmosis, Other (Hepatitis B, HIV, Rubella, Cytomegalovirus, and Herpes Simplex Virus)) pathogens or IPV (Fig. 2).
[IMAGE OMITTED: SEE PDF]
[IMAGE OMITTED: SEE PDF]
Child anthropometry, cognitive development, and behavioral or mental health outcomes were the most frequently measured child outcomes (Fig. 3). Fewer cohorts examined adverse childhood experiences, microbiome composition, or metabolomic profiles.
Nutrition exposures
Thirty-seven of the 56 pregnancy and prepregnancy cohorts (66%) collected data on maternal nutrition during and or after pregnancy. Forty-four individual studies investigated the effects of nutrition-related exposures, and several additional studies included maternal nutrition as a confounder. Eight studies assessed general dietary patterns, overall diet quality, and maternal nutritional status. Additional studies examined prenatal exposure to specific diets (e.g., Mediterranean, gluten-free), nutritional restrictions, or certain foods or drinks (e.g., seafood, caffeine, sweetened beverages). Prenatal intake or deficiency of vitamins and minerals was assessed by 18 studies, which examined maternal vitamin D (n = 10), B12 (n = 1), E (n = 1), calcium (n = 1), iron (n = 2), and iodine intake (n = 7). Studies examined the effect of maternal nutritional exposures on child’s physical health (n = 15), cognitive or neurodevelopmental (n = 16), behavioural and mental health (n = 5), anthropometric (n = 10), and educational (n = 1) outcomes.
Anthropometric measures & non-communicable diseases
Anthropometric measures such as pregpregnancy or maternal BMI, or weight gain during pregnancy were recorded in 42 of the 56 cohorts (75%). Twenty-four cohorts (42%) collected information on maternal exposure to NCDs. Potential participants with any underlying medical conditions, a history of chronic disease, or reporting current physical health issues were excluded from five cohorts. Eight studies included NCDs as the primary exposure. Five of these studies assessed the effects of prenatal thyroid dysfunction on child attention deficit hyperactivity disorder (ADHD) [75], depression and anxiety [76], educational attainment [77], and brain morphology and IQ [78, 79]. One study focused on maternal risk for type 2 diabetes mellitus (T2DM) and child’s cognitive abilities [80]. Another assessed the relationship between late-pregnancy dysglycemia in obese pregnant women and childhood weight gain [81]. One study investigated maternal obesity before pregnancy and child cognitive development [82], and one study examined the effects of maternal preeclampsia and gestational hypertension on childhood and adolescent behavioural problems [7].
Infectious disease and markers of immune function
Nine cohorts (16%) recorded maternal exposure to STORCH pathogens. Six additional cohorts collected medical records or general health information without stating whether those included ID exposures. One study with the Western Australian Pregnancy Cohort data assessed the relationship between prenatal exposure to herpes, rubella, hepatitis B, or rheumatic fever and child-adolescent eating disorders [83]. No other studies examined the relation between ID exposures and child or later life outcomes. Nine cohorts (16%) collected biomarkers related to maternal immune function, including C-reactive protein and T-cell count. Two studies reported on maternal biomarkers and child outcomes. One study from the Rhea Pregnancy Cohort looked at the effect of maternal C-reactive protein on child adiposity [84]. Another study from the Gomeroi Gaaynggal cohort assessed the relationship between maternal T-cell count and child growth, renal disease, and diabetes [59]. We did not identify other pregnancy or prepregnancy cohort studies focusing on the relationship between immune function and child outcomes.
Medication & vaccine exposures
Thirty cohorts (54%) captured data on maternal medication use. Eight studies assessed medication use during pregnancy as the primary exposure. These included investigating the effect of antibiotic use on childhood overweight [85] and diabetes [86], antiepileptic drugs and language development [87], selective serotonin reuptake inhibitors (SSRIs), and language and neurodevelopment [88,89,90,91], thyroid medication and language and motor development [92]. Ten cohorts recorded maternal vaccination status, one of which collected data on COVID-19 vaccination only [93]. We did not identify any cohort studies that aimed to investigate the effects of vaccine exposure during pregnancy.
Environmental exposures
We assessed whether cohorts collected any data on environmental toxins, categorizing them as indoor or outdoor exposures and recording which specific toxins were investigated. As relatively few studies (n = 12) focused on environmental exposures, no patterns emerged regarding specific toxins studied, and the outcomes examined varied widely.
Overall, twenty-eight cohorts (50%) captured exposure to outdoor environmental toxins. Seven studies examined prenatal exposures, including mercury [94, 95], lead [96], long-chain polyunsaturated fatty acids (LCPUFA) [97], polychlorinated biphenyl (PCB) [98], synthetic insecticides [99, 100], gasoline exhaust [101], chemicals used to treat drinking water [102], and any toxin [71]. These studies assessed a range of child health outcomes, including cognitive development [71, 94], neurodevelopment [95, 102], growth [96], leukaemia [101], behaviour [100], and eating disorders [83]. Indoor environmental toxins were measured in 14 (25%) cohorts, with five studies examining the effects of indoor toxins specifically. These included maternal exposure to flame retardants and disinfection by-products in relation to cognitive outcomes [102, 103], per- and poly-fluoroalkyl substances (PFASs) and childhood asthma, allergies, and common IDS [104], phthalates and bisphenols in relation to childhood blood pressure [105], and pyrethroid and chlorpyrifos and child ADHD [99].
Demographic and social exposures
All cohorts recorded socio-demographic factors, including maternal age, educational status, parity, relationship status, personal or household income, and employment status. All studies included several demographic and social measures as control variables. A smaller subset of studies recorded occupation, household size, and country of birth. Twenty-six cohorts (46%) recorded maternal race or ethnicity.
Violence or traumatic events
Eleven cohorts collected IPV data (20%), and three studies assessed IPV as the primary exposure. These examined the effects on the risk of child abuse and neglect [106], child language development [107], and physical growth [108]. No studies focused on maternal exposure to violence other than IPV. One study focused on the effects of flood-related PTSD and prenatal maternal stress in Australian mothers on child school-age anxiety [60]. The effects of maternal mental health, including depression and anxiety, general psychosocial factors, the experience of traumatic life events, and exposure to stress, were explored in 32 studies. One study measured life events during pregnancy typically perceived as stressful and their effects on child language abilities [109].
Child outcomes
Additional File 7 details the types of infant and child outcomes measured across pregnancy and prepregnancy cohorts. Fifty-one (91%) cohorts collected infant or child anthropometric data. Most cohorts also collected data on childhood NCDs (e.g., asthma, eczema, allergies) or other physical outcomes (n = 42), child nutrition (n = 38), cognitive development (n = 38), and behavioural or mental health outcomes, including infant sleeping patterns, crying, depression, eating disorders, and externalising or internalising behaviour (n = 38). The least common outcomes measured by cohorts included growth curves (n = 3), microbiome (n = 4), economic outcomes (n = 5), the experience of violence and stressful events (n = 12), metabolomics (n = 9), and immune function (n = 9). Fourteen (25%) and 17 (30%) cohorts recorded child vaccination status and medication use, respectively. We identified 64 studies that focused on the effects of various prenatal exposures on children’s cognitive development, behavioural outcomes, or mental health. Thirty-five studies measured physical outcomes in children, including blood pressure, bone mineral content or bone mass, and NCDs, including diabetes, allergies, asthma, and leukaemia, among others. Sixteen studies examined anthropometric measures as the primary child outcome, including general growth, skeletal growth, weight gain, and childhood obesity or overweight. Educational outcomes and experience of violence and stress were assessed by four and two studies, respectively.
Sample collection and availability
Cohort sample collection is detailed in Additional File 8. One of the two prepregnancy cohorts did not collect any samples [56]; the other collected maternal samples before and during pregnancy and fetal samples at birth [12]. Thirty-six of the 56 pregnancy and prepregnancy cohorts (64%) collected at least one type of sample during pregnancy, the most common ones being blood (n = 33), urine (n = 16), saliva (n = 8), and hair (n = 7). The timing and frequency of sample collection during pregnancy varied across cohorts. Most studies collected samples twice during pregnancy. Some studies focused on specific trimesters, with the first and third being commonly targeted. A detailed description of the timing and frequency of sample collection can be found in Additional File 8. Eight cohorts collected paternal samples during or following pregnancy. Twenty-seven cohorts (48%) included fetal samples, including cord blood or placental tissue, usually taken at birth. Sixteen and 21 cohorts collected infant and child samples, respectively. Most publications did not indicate whether samples were available to outside researchers. Through additional research, we were able to identify biobanks or biorepositories and sample access procedures for the MoBa [110], Avon Longitudinal Study of Parents And Children (ALSPAC) [93], Scandinavian Successive Small for Gestational Age (SGA) [111], and Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) [112] cohorts.
Platforms that host data from pregnancy and prepregnancy cohorts
Whether data had been shared to a registry or platform to facilitate its reuse could not be determined from most publications. Where data-sharing policies were mentioned in publications, studies said data could be made available upon reasonable request to the authors [71, 90, 113, 114]. Through reviewing study websites, we were able to identify data access procedures for 7 of the 56 cohorts, including the ALSPAC [93], Conditions Affecting Neurocognitive Development and Learning in Early Childhood (CANDLE) [115], CHAMACOS [112], DNBC [63], MoBa [110], SGA [111], and the Vitamin D in Pregnancy Cohort [116].
Discussion
In this comprehensive scoping review, we extracted data from 127 studies representing 54 pregnancy and two prepregnancy cohorts that followed infants and children beyond two years of age. Anthropometric measures, nutrition, and NCDs were the most commonly measured maternal exposures. Over half of included studies investigated child anthropometric, cognitive development, behaviour, and mental health outcomes. Half of the cohorts were based in Europe. While Africa and Asia host most of the world’s population, only 6 pregnancy cohorts were located there.
What we don’t know can be as informative as what we know. While many studies examined the relationship between dietary and vitamin exposures during pregnancy and later life outcomes, only a few cohorts recorded maternal exposure to ID and child outcomes and only one study considered ID as the primary maternal exposure. The lack of focus on ID exposures during pregnancy may be because of difficulties in measuring incident infections or because IDs are a lesser concern for the high-income countries (HICs) where most of the cohorts were based. Infections during pregnancy may be asymptomatic or present with nonspecific symptoms, making clinical detection difficult [117]. Additionally, standard diagnostic tools may lack the sensitivity or specificity required to ascertain the timing of infection relative to gestational age, which significantly influences outcomes, further complicating ID ascertainment in pregnancy [118]. In HICs, the prevalence and impact of ID during pregnancy are generally lower due to better healthcare infrastructure, widespread immunization programs, and improved sanitation [119, 120]. Consequently, research priorities in these regions may focus on NCDs, leading to an underrepresentation of ID exposures in pregnancy cohorts based in HICs. That said, the recent rise in infant deaths related to congential syphilis in Queensland, Australia highlights the ongoing relevance of studying IDs during pregnancy, even in HICs [121]. The need for improved data on maternal infectious exposures is particularly evident during public health emergencies. The 2015–17 ZIKV epidemic highlighted the importance of pregnancy and prepregnancy cohorts in the context of emerging infectious diseases [122]. In light of this, our findings emphasize the importance of enhancing exposure measurement practices within cohorts.
The stage and intensity of infection and timing of treatment initiation are strong predictors of pregnancy outcomes and likely related to the incidence and spectrum of later-life developmental effects, therefore, pregnancy cohorts should aim to record and systematically monitor ID exposures [123, 124]. A systematic review of maternal syphilis and pregnancy outcomes found that studies of infectious exposures in pregnant women had limited follow-up time, were restricted to symptomatic pregnant women, and were subject to misclassification and selection bias when infection was not captured by serology because of test sensitivity or when infection occurred following the study visit [125]. Studies of STORCH pathogens generally focus on pregnancy outcomes rather than longer-term effects [32, 125]. Many STORCH studies do not consider the possibility of co-infection [126], and some STORCH infections are not included in routine pregnancy screening [127, 128].
The lack of systematic exposure assessment was also evident in studies examining medications and vaccinations during pregnancy. Similar to ID exposures, only a few included studies assessed exposure to medicines during pregnancy. These studies evaluated the relation between maternal antibiotics, antiepileptic drugs, and SSRI use and child outcomes. While a few studies asked about vaccine histories, we did not identify any studies of vaccine exposures during pregnancy. Systematic reviews of studies of vaccine exposures during pregnancy found that existing studies were limited and focused on immediate infant rather than longer-term child outcomes [113, 129,130,131,132,133]. This limited scope leaves significant uncertainty regarding the developmental and health impacts of prenatal vaccine exposure beyond the neonatal period.
This gap in exposure data is compounded by the broader issue of pregnant women being underrepresented in safety and efficacy studies. They are generally excluded from vaccine and medication safety and efficacy studies, making it difficult for pregnant women and providers to make informed decisions about vaccination or medication use during pregnancy. Pregnancy cohorts typically lack information on drug and medication exposures, and pregnancy registry data lacks information on medication exposures [134]. Selection bias, small sample size, retrospective and self-reported data collection, and inadequate information on timing and dosage complicate the assessment of medication exposures during pregnancy [134]. Most pharmacovigilance studies that include pregnant women are cross-sectional [135], precluding causality assessment. Cohort data on maternal medication and vaccine exposures can facilitate post-marketing assessment of the risks and benefits of maternal medication exposure and longer-term child outcomes.
Other critical but underexamined exposures include those related to climate and the environment. Although climate-related exposures, including extreme heat, wildfire smoke, and flooding, are increasingly recognized as significant threats to MCH, we did not identify any pregnancy or prepregnancy cohorts that measured these exposures. Studies on the relationship between environmental or workplace exposures and child outcomes were also limited, given the number of potential exposures of concern. This absence may reflect historical underprioritization of climate-health linkages in maternal and child research or methodological challenges in linking geospatial environmental data to individual-level pregnancy records. Climate-related exposures often vary by region and season, requiring granular data and long-term follow-up to detect meaningful associations. Addressing these gaps will require the integration of environmental monitoring and cohort data, investment in climate-sensitive exposure assessment tools, and prioritization of MCH research that relates to vulnerable populations in regions experiencing disproportionate climate-related health burdens.
Other important social determinants of health were also sparsely assessed. While 11 cohorts collected data on IPV, only three studies included IPV as the exposure of interest. Fewer than half of the cohorts measured race, an important marker of child health outcomes.
Biological sample collection varied across cohorts, with notable gaps in follow-up. Over 60% of cohorts collected samples during pregnancy, and about half collected fetal samples. Fewer than half collected infant or child samples. Blood was the most commonly collected sample type. Most publications did not describe how to access pregnancy or prepregnancy cohort data or samples, although we were able to identify access procedures for four cohorts through their websites. We only identified two prepregnancy cohorts, representing a missed opportunity to understand how prior exposures affect pregnancy, fetal, infant, and child outcomes. The lack of guidance on how to access pregnancy and prepregnancy cohort data and biospecimens may reflect a range of structural, ethical, and logistical barriers. Data and sample sharing require clearly specified, well-structured governance procedures, broad consent for future use from research subjects, data and sample use agreements, and material transfer agreements, which may deter investigators from formalizing access procedures or sharing at all. Additionally, concerns over participant privacy, especially for sensitive exposures and biospecimens, may limit transparency. In some cases, cohorts may lack the infrastructure, funding, or personnel needed to support data and sample sharing, particularly if the original studies were not designed with long-term access or interoperability in mind. Addressing these barriers will require investments in data governance frameworks that support secure and equitable sharing, clear communication of access procedures, harmonization of cohort metadata to facilitate discoverability, and support to address concerns around broad consent for future use.
Improving data accessibility would be essential to unlocking the full potential of existing cohorts. We were not able to identify how data could be accessed for most cohorts from the cohort publications. Further work could explore how cohort metadata catalogues, e.g., Cohort and Longitudinal Studies Enhancement Resources (CLOSER), the European Open Science Cloud (EOSC), or other cohort metadata catalogues, could be used to identify cohorts that collect specific exposure or outcome data and how those data can be accessed.
Strengths & limitations
Our scoping review had several important strengths. The comprehensive information on the landscape of pregnancy and prenatal cohorts that follow infants to at least two years of age can help researchers and funders understand the focus of existing studies and identify gaps in coverage of maternal exposures and associated child outcomes. We did not limit our search by geography or language of publication. We extracted data from included publications and looked for additional information on the identified cohorts from related websites and other publicly available documentation. The review has some limitations. While we aimed to comprehensively capture existing pregnancy and prepregnancy cohorts that followed infants to at least two years, some may have been missed despite our extensive search strategy. Because the search strategy targeted publications rather than cohort websites, cohort publications that did not meet the inclusion criteria were excluded even when the cohort itself could have been included if the inclusion criteria had been applied to the cohort. We did not search the websites of all cohorts screened in the title-abstract or full text phases, so we could have missed including pregnancy or pregnancy cohorts that reported a study population recruited at birth, even though the larger initiative also included women recruited during pregnancy. Additionally, we relied on available publications, cohort websites, and other cohort-related documentation to comprehensively describe exposures and outcomes measured, meaning that data collected within cohorts that were not explicitly reported in the publication or associated documentation would not have been reported here. Cohort sizes might be overestimated, as we recorded the number of recruited participants with at least one follow-up, but did not take into consideration dropouts or missed follow-up visits. Similarly, while we categorized follow-up frequency of infants and children (e.g., more frequent in the first three years of life), we did not systematically document the exact ages of follow-up assessments. Lastly, since we chose to focus this review on pregnancy and prepregnancy cohorts that followed infants to at least two years of age, we did not describe the many thousands of pregnancy and prepregnancy cohorts that describe fetal and infant outcomes from birth until before two years of age.
Policy recommendations
Table 2 provides a summary of review findings as they relate to different maternal exposures, including recommendations for future research investments. Only a few included cohorts assessed maternal exposure to medications, antibiotics, antiepileptic drugs, or SSRIs and even fewer asked about vaccine histories. No studies evaluated vaccine exposures during pregnancy as a primary focus. Existing studies of maternal vaccine and medication exposures are typically limited by small sample sizes, selection bias, retrospective and self-reported data collection, and inadequate information on timing and dosage. Most pharmacovigilance studies involving pregnant women are cross-sectional, which restricts the ability to assess causality. Moreover, pregnancy cohorts rarely include standardized, prospective monitoring of medication or vaccine exposures, and registry data often lack detail on long-term child outcomes.
[IMAGE OMITTED: SEE PDF]
To address these limitations, future pregnancy and prepregnancy cohorts should incorporate structured data collection tools to capture medication, vaccine, and infectious disease exposures with precise timing and dosage information, ideally through linkage with electronic health records or prescription registries. Systematic screening for STORCH pathogens, including co-infections, and inclusion of both symptomatic and asymptomatic infections would improve the quality of maternal ID exposure ascertainment. Longer term follow-up, combined with harmonized exposure definitions and integration with pharmacovigilance systems, would support more robust assessment of the relation between medication and vaccine exposures and long-term developmental outcomes and enhance the utility of cohorts for informing clinical and regulatory decision-making.
To improve coordination and data harmonization across cohorts, stakeholders could prioritize the development and adoption of common data elements, use of shared ontologies, and metadata catalogues to enable efficient discovery and cross-study synthesis of variables for pooled analyses. For example, researchers could leverage cohorts identified in this review to conduct pooled analyses on the impact of prenatal exposures (e.g., environmental toxins, maternal mental health) on adolescent mental health outcomes using harmonized variables. Initiatives such as the Maelstrom Research Metadata Catalogue [136] and the Global Pregnancy CoLab [137] can serve as platforms to promote interoperability and data reuse.
Key research priorities emerging from this review include identifying context-specific and common maternal exposures influencing long-term child development, examining intergenerational effects of preconception exposures, and addressing how social determinants and maternal ID and environmental exposures influence developmental trajectories.
Conclusions
Prepregnancy and pregnancy exposures are central to understanding the distribution of birth and later-life developmental outcomes. The most commonly described maternal exposures for pregnancy and prepregnancy cohorts were nutrition, NCDs, and demographic factors. Children’s mental, behavioural, neurodevelopmental, and physical outcomes were the most commonly measured outcomes. Maternal ID, medication, climate, environmental, and vaccine exposures and infant or child outcomes like microbiome, immune function, and economic impacts were underrepresented. While core perinatal exposures such as nutrition, anthropometry, and sociodemographic factors were commonly measured, critical exposures with implications for public health and health equity, including IDs, medication and vaccine use, environmental hazards, and climate-related exposures, were substantially underrepresented in pregnancy and prepregnancy cohorts. To support meaningful causal inference and advance MCH research, future cohorts should prioritize systematic measurement of these exposures, integrate longitudinal follow-up beyond infancy, and establish transparent data and sample access protocols.
Coordination between pregnancy and prepregnancy cohorts can facilitate cross-population inference and build a better understanding of how maternal exposures shape later-life cognitive, behavioural, and developmental outcomes. Our findings can help researchers understand what resources exist to explore the relation between maternal exposures and child, adolescent, or adult offspring outcomes. This mapping exercise can also inform efforts to reuse participant-level data across ongoing or completed pregnancy and prepregnancy cohorts and support the development of a research agenda to set priorities for future investments to understand the proximal causes of short and long-term adverse developmental outcomes or chronic conditions.
Data availability
The author confirms that all data generated or analysed during this study are included in this published article and its supplementary information files.
Abbreviations
ADHD:
Attention deficit hyperactivity disorder
ALSPAC:
Avon Longitudinal Study of Parents And Children
BMI:
Body-mass index
CANDLE:
Conditions Affecting Neurocognitive Development and Learning in Early Childhood
CHAMACOS:
Center for the Health Assessment of Mothers and Children of Salinas
CHD:
Congenital Heart Disease
CMV:
Cytomegalovirus
COVID-19:
Coronavirus Disease 2019
CVD:
Cardiovascular Disease
DNBC:
Danish National Birth Cohort
ELSPAC:
European Longitudinal Study of Pregnancy and Childhood
HICs:
High-income countries
HSV:
Herpes simplex virus
ID:
Infectious disease
IPV:
Intimate Partner Violence
LBW:
Low birth weight
LCPUFA:
Long-chain polyunsaturated fatty acids
MCH:
Maternal and child health
MeSH:
Medical Subject Headings
NCD:
Non-communicable disease
PCB:
Polychlorinated biphenyl
PFASs:
Per- and Poly-Fluoralkyl Substances
PRISMA:
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PRISMA-ScR:
PRISMA Extension for Scoping Reviews
PTSD:
Post-Traumatic Stress Disorder
RCTs:
Randomized Controlled Trials
SGA:
Small for Gestational Age
SSRIs:
Selective serotonin reuptake inhibitors
STORCH:
Syphilis, Toxoplasmosis, Other (Hepatitis B, HIV, Rubella, Cytomegalovirus, and Herpes Simplex Virus)
T2DM:
Type 2 diabetes mellitus
ZIKV:
Zika virus
Ballot DE, Ramdin T, Rakotsoane D, Agaba F, Davies VA, Chirwa T, Cooper PA. Use of the Bayley scales of infant and toddler development, third edition, to assess developmental outcome in infants and young children in an urban setting in South Africa. Int Sch Res Notices. 2017;2017(1):1631760.
Lipkin PH, Macias MM, Council on children with disabilities sod, pediatrics B. Promoting optimal development: identifying infants and young children with developmental disorders through developmental surveillance and screening. Pediatrics. 2020. https://doi.org/10.1542/peds.2019-3449.
Godfrey KM, Reynolds RM, Prescott SL, Nyirenda M, Jaddoe VWV, Eriksson JG, Broekman BFP. Influence of maternal obesity on the long-term health of offspring. Lancet Diabetes Endocrinol. 2017;5(1):53–64.
Veena SR, Gale CR, Krishnaveni GV, Kehoe SH, Srinivasan K, Fall CH. Association between maternal nutritional status in pregnancy and offspring cognitive function during childhood and adolescence; a systematic review. BMC Pregnancy Childbirth. 2016;16:220.
Arija V, Canals J. Effect of maternal nutrition on cognitive function of children. Nutrients. 2021. https://doi.org/10.3390/nu13051644.
Dionne G, Boivin M, Seguin JR, Perusse D, Tremblay RE. Gestational diabetes hinders language development in offspring. Pediatrics. 2008;122(5):e1073–9.
Robinson M, Mattes E, Oddy WH, de Klerk NH, Li J, McLean NJ, et al. Hypertensive diseases of pregnancy and the development of behavioral problems in childhood and adolescence: the Western Australian Pregnancy Cohort Study. The Journal of pediatrics. 2009;154(2):218–24. e2.
Marbán-Castro E, Vazquez Guillamet LJ, Pantoja PE, Casellas A, Maxwell L, Mulkey SB, et al. Neurodevelopment in normocephalic children exposed to Zika virus in utero with no observable defects at birth: a systematic review with meta-analysis. Int J Environ Res Public Health. 2022;19(12): 7319.
Nogueira Avelar ESR, Yu Y, Liew Z, Vested A, Sorensen HT, Li J. Associations of Maternal Diabetes During Pregnancy With Psychiatric Disorders in Offspring During the First 4 Decades of Life in a Population-Based Danish Birth Cohort. JAMA Netw Open. 2021;4(10): e2128005.
He JR, Ramakrishnan R, Hirst JE, Bonaventure A, Francis SS, Paltiel O, et al. Maternal Infection in Pregnancy and Childhood Leukemia: A Systematic Review and Meta-analysis. J Pediatr. 2020;217:98-109.e8.
Tran NT, Nguyen LT, Berde Y, Low YL, Tey SL, Huynh DTT. Maternal nutritional adequacy and gestational weight gain and their associations with birth outcomes among Vietnamese women. BMC Pregnancy Childbirth. 2019;19(1):468.
Young MF, Ramakrishnan U. Maternal undernutrition before and during pregnancy and offspring health and development. Ann Nutr Metab. 2021. https://doi.org/10.1159/000510595.
Bhowmik B, Siddique T, Majumder A, Mdala I, Hossain IA, Hassan Z, et al. Maternal BMI and nutritional status in early pregnancy and its impact on neonatal outcomes at birth in Bangladesh. BMC Pregnancy Childbirth. 2019;19(1):413.
Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet. 2013;382(9890):427–51.
Yuan X, Liu Z, Zhu J, Yu P, Deng Y, Chen X, et al. Association between prepregnancy body mass index and risk of congenital heart defects in offspring: an ambispective observational study in China. BMC Pregnancy Childbirth. 2020;20(1):444.
Hassan HE. Fetal and neonatal complications of pregnancy-induced hypertension. American Research Journal of Public Health. 2020;3(1):1–3.
Gogoi M, Unisa S. Chronic diseases during pregnancy and birth outcome: a study based on tertiary hospital of Mumbai. Women’s Health - Open Journal. 2017;3(2):61–8.
Lawlor DA, Lichtenstein P, Langstrom N. Association of maternal diabetes mellitus in pregnancy with offspring adiposity into early adulthood: sibling study in a prospective cohort of 280,866 men from 248,293 families. Circulation. 2011;123(3):258–65.
Health SCs. Diabetes During Pregnancy 2022 [Available from: https://www.stanfordchildrens.org/en/topic/default?id=diabetes-and-pregnancy-90-P02444.
Norman M, Naver L, Soderling J, Ahlberg M, Hervius Askling H, Aronsson B, et al. Association of maternal SARS-CoV-2 infection in pregnancy with neonatal outcomes. JAMA. 2021;325(20):2076–86.
Kotlar B, Gerson E, Petrillo S, Langer A, Tiemeier H. The impact of the COVID-19 pandemic on maternal and perinatal health: a scoping review. Reprod Health. 2021;18(1):10.
Friedman EE, Dallah F, Harville EW, Myers L, Buekens P, Breart G, Carles G. Symptomatic dengue infection during pregnancy and infant outcomes: a retrospective cohort study. PLoS Negl Trop Dis. 2014;8(10): e3226.
Garrison A, Boivin MJ, Fiévet N, Zoumenou R, Alao JM, Massougbodji A, et al. The effects of malaria in pregnancy on neurocognitive development in children at 1 and 6 years of age in Benin: a prospective mother-child cohort. Clin Infect Dis. 2022;74(5):766–75.
Martins MM, Alves da Cunha AJL, Robaina JR, Raymundo CE, Barbosa AP, Medronho RdA. Fetal, neonatal, and infant outcomes associated with maternal Zika virus infection during pregnancy: A systematic review and meta-analysis. PLOS ONE. 2021;16(2):e0246643.
De Santis M, De Luca C, Mappa I, Spagnuolo T, Licameli A, Straface G, Scambia G. Syphilis Infection during pregnancy: fetal risks and clinical management. Infect Dis Obstet Gynecol. 2012;2012:1–5.
Xiong Y-q, Tan J, Liu Y-m, He Q, Li L, Zou K, Sun X. The risk of maternal parvovirus B19 infection during pregnancy on fetal loss and fetal hydrops: a systematic review and meta-analysis. J Clin Virol. 2019;114:12–20.
Duszak RS. Congenital rubella syndrome—major review. Optometry - Journal of the American Optometric Association. 2009;80(1):36–43.
Shi TL, Huang LJ, Xiong YQ, Zhong YY, Yang JJ, Fu T, et al. The risk of herpes simplex virus and human cytomegalovirus infection during pregnancy upon adverse pregnancy outcomes: a meta-analysis. J Clin Virol. 2018;104:48–55.
Mahic M, Mjaaland S, Bovelstad HM, Gunnes N, Susser E, Bresnahan M, et al. Maternal Immunoreactivity to Herpes Simplex Virus 2 and Risk of Autism Spectrum Disorder in Male Offspring. mSphere. 2017;2(1).
Blomstrom A, Karlsson H, Gardner R, Jorgensen L, Magnusson C, Dalman C. Associations between maternal infection during pregnancy, childhood infections, and the risk of subsequent psychotic disorder–a Swedish cohort study of nearly 2 million individuals. Schizophr Bull. 2016;42(1):125–33.
Stephen L. Buka SMTT, MD, PhD; E. Fuller Torrey, MD; Mark A. Klebanoff, MD; David Bernstein, MD; Robert H. Yolken, MD. Maternal Infections and Subsequent Psychosis Among Offspring. Arch Gen Psychiatry. 2001;58:1032–7.
al-Haddad BJS, Oler E, Armistead B, Elsayed NA, Weinberger DR, Bernier R, et al. The fetal origins of mental illness. Am J Obstet Gynecol. 2019;221(6):549–62.
Hcini N, Kugbe Y, Rafalimanana ZHL, Lambert V, Mathieu M, Carles G, et al. Association between confirmed congenital Zika infection at birth and outcomes up to 3 years of life. Nat Commun. 2021;12(1):3270.
Mawson AR, Croft AM. Rubella virus infection, the congenital rubella syndrome, and the link to autism. Int J Environ Res Public Health. 2019. https://doi.org/10.3390/ijerph16193543.
Carvalho ALd, Ventura P, Taguchi T, Brandi I, Brites C, Lucena R. Cerebral palsy in children with congenital Zika syndrome: a 2-year neurodevelopmental follow-up. J Child Neurol. 2020;35(3):202–7.
Sever JL, South MA, Shaver KA. Delayed manifestations of congenital rubella. Rev Infect Dis. 1985;7(Supplement_1):S164–9.
Kimberlin DW, Lin C-Y, Jacobs RF, Powell DA, Frenkel LM, Gruber WC, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108(2):223–9.
Demmler-Harrison GJ, Miller JA. Maternal cytomegalovirus immune status and hearing loss outcomes in congenital cytomegalovirus-infected offspring. PLoS ONE. 2020;15(10): e0240172.
Cristina da Silva Rosa B, Hernandez Alves Ribeiro César CP, Paranhos LR, Guedes-Granzotti RB, Lewis DR. Speech-language disorders in children with congenital Zika virus syndrome: A systematic review. International Journal of Pediatric Otorhinolaryngology. 2020;138:110309.
Simoncic V, Deguen S, Enaux C, Vandentorren S, Kihal-Talantikite W. A comprehensive review on social inequalities and pregnancy outcome-identification of relevant pathways and mechanisms. Int J Environ Res Public Health. 2022. https://doi.org/10.3390/ijerph192416592.
Braveman P, Dominguez TP, Burke W, Dolan SM, Stevenson DK, Jackson FM, et al. Explaining the black-white disparity in preterm birth: a consensus statement from a multi-disciplinary scientific work group convened by the March of Dimes. Front Reprod Health. 2021. https://doi.org/10.3389/frph.2021.684207.
Guo G, Harris KM. The mechanisms mediating the effects of poverty on children’s intellectual development. Demography. 2000;37(4):431–47.
Toso K, de Cock P, Leavey G. Maternal exposure to violence and offspring neurodevelopment: a systematic review. Paediatr Perinat Epidemiol. 2020;34(2):190–203.
Alhusen JL, Ray E, Sharps P, Bullock L. Intimate partner violence during pregnancy: maternal and neonatal outcomes. J Womens Health (Larchmt). 2015;24(1):100–6.
Saulnier DD, Brolin K. A systematic review of the health effects of prenatal exposure to disaster. Int J Public Health. 2015;60(7):781–7.
Pullar J, Wickramasinghe K, Demaio AR, Roberts N, Perez-Blanco KM, Noonan K, Townsend N. The impact of maternal nutrition on offspring’s risk of non-communicable diseases in adulthood: a systematic review. J Glob Health. 2019;9(2): 020405.
Newman T. Famine in pregnancy impacts offspring's mental health in adulthood 2017 [Available from: Famine in pregnancy impacts offspring's mental health in adulthood.
Stein AD, Pierik FH, Verrips GH, Susser ES, Lumey LH. Maternal exposure to the Dutch famine before conception and during pregnancy: quality of life and depressive symptoms in adult offspring. Epidemiology. 2009;20(6):909–15.
Liu S, Jones RN, Glymour MM. Implications of lifecourse epidemiology for research on determinants of adult disease. Public Health Rev. 2010;32(2):489–511.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.
Maxwell L, Gilyan R, Chavan SA, Al-Zumair M, Akter S, Jaenisch T. Pre-pregnancy and pregnancy cohorts: a scoping review protocol. F1000Res. 2021. https://doi.org/10.12688/f1000research.55501.1.
Covidence. Covidence Systematic Review Software. Melbourne, Australia2017.
Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(1):69.
Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.
Ogaz-González R, Mérida-Ortega Á, Torres-Sánchez L, Schnaas L, Hernández-Alcaraz C, Cebrián ME, et al. Maternal dietary intake of polyunsaturated fatty acids modifies association between prenatal DDT exposure and child neurodevelopment: a cohort study. Environ Pollut. 2018;238:698–705.
Loo EXL, Soh S-E, Loy SL, Ng S, Tint MT, Chan S-Y, et al. Cohort profile: Singapore preconception study of long-term maternal and child outcomes (S-PRESTO). Eur J Epidemiol. 2021;36:129–42.
Stein LJ, Gunier RB, Harley K, Kogut K, Bradman A, Eskenazi B. Early childhood adversity potentiates the adverse association between prenatal organophosphate pesticide exposure and child IQ: the CHAMACOS cohort. Neurotoxicology. 2016;56:180–7.
Ashman AM, Collins CE, Weatherall L, Brown LJ, Rollo ME, Clausen D, et al. A cohort of Indigenous Australian women and their children through pregnancy and beyond: the Gomeroi gaaynggal study. J Dev Orig Health Dis. 2016;7(4):357–68.
McLean MA, Simcock G, Elgbeili G, Laplante DP, Kildea S, Hurrion E, et al. Disaster-related prenatal maternal stress, and childhood HPA-axis regulation and anxiety: the QF2011 Queensland flood study. Psychoneuroendocrinology. 2020;118: 104716.
Janjua NZ, Mahmood B, Islam MA, Goldenberg RL. Maternal and early childhood risk factors for overweight and obesity among low-income predominantly black children at age five years: a prospective cohort study. Journal of obesity. 2012;2012.
Costa VPP, Correa MB, Goettems ML, Pinheiro RT, Demarco FF. Maternal depression and anxiety associated with dental fear in children: a cohort of adolescent mothers in Southern Brazil. Brazilian oral research. 2017;31.
Olsen J, Melbye M, Olsen SF, Sørensen TI, Aaby P, Nybo Andersen A-M, et al. The Danish national birth cohort-its background, structure and aim. Scand J Public Health. 2001;29(4):300–7.
Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, et al. Cohort profile update: the Norwegian mother and child cohort study (MoBa). Int J Epidemiol. 2016;45(2):382–8.
Najman J, Bor W, O’Callaghan M, Williams G, Aird R, Shuttlewood G. Cohort profile: the mater-University of Queensland study of pregnancy (MUSP). Int J Epidemiol. 2005;34(5):992–7.
Hounsgaard ML, Håkonsen LB, Vested A, Thulstrup AM, Olsen J, Bonde JP, et al. Maternal pre-pregnancy body mass index and pubertal development among sons. Andrology. 2014;2(2):198–204.
Straker LM, Hall GL, Mountain J, Howie EK, White E, McArdle N, Eastwood PR. Rationale, design and methods for the 22 year follow-up of the Western Australian Pregnancy Cohort (Raine) Study. BMC Public Health. 2015;15(1):1–16.
Center UoRM. Seychelles Child Development Study: Scientific Approach 2023 [Available from: https://www.urmc.rochester.edu/labs/seychelles/scientific-approach.aspx.
Ester WA, Houghton LC, Lumey LH, Michels KB, Hoek HW, Wei Y, et al. Maternal and early childhood determinants of women’s body size in midlife: overall cohort and sibling analyses. Am J Epidemiol. 2017;185(5):385–94.
Piler P, Kandrnal V, Kukla L, Andrýsková L, Švancara J, Jarkovský J, et al. Cohort profile: the european longitudinal study of pregnancy and childhood (ELSPAC) in the Czech Republic. International Journal of Epidemiology. 2017;46(5):1379-f.
Zijlmans W, Wickliffe J, Hindori-Mohangoo A, MacDonald-Ottevanger S, Ouboter P, Landburg G, et al. Caribbean Consortium for Research in Environmental and Occupational Health (CCREOH) cohort study: influences of complex environmental exposures on maternal and child health in Suriname. BMJ Open. 2020;10(9): e034702.
Guxens M, Ballester F, Espada M, Fernández MF, Grimalt JO, Ibarluzea J, et al. Cohort profile: the INMA—INfancia y Medio Ambiente—(Environment and Childhood) project. Int J Epidemiol. 2011;41(4):930–40.
Mekonnen H, Medhin G, Tomlinson M, Alem A, Prince M, Hanlon C. Impact of maternal common mental disorders on child educational outcomes at 7 and 9 years: a population-based cohort study in Ethiopia. BMJ Open. 2018;8(1): e018916.
Brown SJ, Gartland D, Woolhouse H, Giallo R, McDonald E, Seymour M, et al. The maternal health study: study design update for a prospective cohort of first-time mothers and their firstborn children from birth to age ten. Paediatr Perinat Epidemiol. 2021;35(5):612–25.
Fetene DM, Betts KS, Alati R. Maternal prenatal thyroid function and offspring ADHD: findings from the ALSPAC cohort. J Nerv Ment Dis. 2018;206(11):859–64.
Fetene DM, Betts K, Alati R. The role of maternal prenatal thyroid function on offspring depression: Findings from the ALSPAC cohort. Psychoneuroendocrinology. 2019;100:S7-S.
Nelson SM, Haig C, McConnachie A, Sattar N, Ring SM, Smith GD, et al. Maternal thyroid function and child educational attainment: prospective cohort study. bmj. 2018;360.
Jansen TA, Korevaar TI, Mulder TA, White T, Muetzel RL, Peeters RP, Tiemeier H. Maternal thyroid function during pregnancy and child brain morphology: a time window-specific analysis of a prospective cohort. Lancet Diabetes Endocrinol. 2019;7(8):629–37.
Korevaar TI, Muetzel R, Medici M, Chaker L, Jaddoe VW, de Rijke YB, et al. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(1):35–43.
Bonilla C, Lawlor DA, Ben-Shlomo Y, Ness AR, Gunnell D, Ring SM, et al. Maternal and offspring fasting glucose and type 2 diabetes-associated genetic variants and cognitive function at age 8: a Mendelian randomization study in the Avon Longitudinal Study of Parents and Children. BMC Med Genet. 2012;13:90.
Gomes D, von Kries R, Delius M, Mansmann U, Nast M, Stubert M, et al. Late-pregnancy dysglycemia in obese pregnancies after negative testing for gestational diabetes and risk of future childhood overweight: an interim analysis from a longitudinal mother–child cohort study. PLoS Med. 2018;15(10): e1002681.
Casas M, Forns J, Martínez D, Guxens M, Fernandez-Somoano A, Ibarluzea J, et al. Maternal pre-pregnancy obesity and neuropsychological development in pre-school children: a prospective cohort study. Pediatr Res. 2017;82(4):596–606.
Allen KL, Byrne SM, Forbes D, Oddy WH. Risk factors for full- and partial-syndrome early adolescent eating disorders: a population-based pregnancy cohort study. J Am Acad Child Adolesc Psychiatry. 2009;48(8):800–9.
Daraki V, Georgiou V, Papavasiliou S, Chalkiadaki G, Karahaliou M, Koinaki S, et al. Metabolic profile in early pregnancy is associated with offspring adiposity at 4 years of age: the Rhea pregnancy cohort Crete, Greece. PLoS ONE. 2015;10(5): e0126327.
Jess T, Morgen CS, Harpsoe MC, Sorensen TIA, Ajslev TA, Antvorskov JC, Allin KH. Antibiotic use during pregnancy and childhood overweight: a population-based nationwide cohort study. Sci Rep. 2019;9(1):11528.
Haupt-Jorgensen M, Morgen CS, Jess T, Buschard K, Josefsen K, Allin KH, Antvorskov JC. Maternal antibiotic use during pregnancy and type 1 diabetes in children-a national prospective cohort study. Diabetes Care. 2018;41(12):e155–7.
Husebye ESN, Gilhus NE, Spigset O, Daltveit AK, Bjork MH. Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero - the Norwegian Mother and Child Cohort Study. Eur J Neurol. 2020;27(4):667–75.
Skurtveit S, Selmer R, Roth C, Hernandez-Diaz S, Handal M. Prenatal exposure to antidepressants and language competence at age three: results from a large population-based pregnancy cohort in Norway. BJOG : an international journal of obstetrics and gynaecology. 2014;121(13):1621–31.
van der Veere CN, de Vries NKS, van Braeckel KNJA, Bos AF. Intra-uterine exposure to selective serotonin reuptake inhibitors (SSRIs), maternal psychopathology, and neurodevelopment at age 2.5years - results from the prospective cohort SMOK study. Early Hum Dev. 2020;147: 105075.
Dhaliwal G, Weikum WM, Jolicoeur-Martineau A, Brain U, Grunau RE, Oberlander TF. Effects of maternal depression and prenatal SSRI exposure on executive functions and susceptibility to household chaos in 6-year-old children: prospective cohort study. BJPsych Open. 2020;6(5): e106.
Handal M, Skurtveit S, Furu K, Hernandez-Diaz S, Skovlund E, Nystad W, Selmer R. Motor development in children prenatally exposed to selective serotonin reuptake inhibitors: a large population-based pregnancy cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2016;123(12):1908–17.
van den Broek S, Lupattelli A, Frank AS, Haug LS, Nordeng H. Thyroid hormone replacement therapy in pregnancy and motor function, communication skills, and behavior of preschool children: the Norwegian mother, father, and child cohort study. Pharmacoepidemiol Drug Saf. 2020. https://doi.org/10.1002/pds.5184.
Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al. Cohort profile: the ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013;42(1):111–27.
Golding J, Hibbeln JR, Gregory SM, Iles-Caven Y, Emond A, Taylor CM. Maternal prenatal blood mercury is not adversely associated with offspring IQ at 8 years provided the mother eats fish: A British prebirth cohort study. Int J Hyg Environ Health. 2017;220(7):1161–7.
Huang L-S, Cory-Slechta DA, Cox C, Thurston SW, Shamlaye CF, Watson GE, et al. Analysis of nonlinear associations between prenatal methylmercury exposure from fish consumption and neurodevelopmental outcomes in the Seychelles Main Cohort at 17 years. Stoch Environ Res Risk Assess. 2018;32:893–904.
Renzetti S, Just AC, Burris HH, Oken E, Amarasiriwardena C, Svensson K, et al. The association of lead exposure during pregnancy and childhood anthropometry in the Mexican PROGRESS cohort. Environ Res. 2017;152:226–32.
Sun Y, Vestergaard M, Christensen J, Olsen J, Olsen SF. Intake of marine n-3 fatty acids during pregnancy and risk for epilepsy in the offspring: a population-based cohort study. Epilepsy Res. 2010;91(2–3):267–72.
Caspersen IH, Kvalem HE, Haugen M, Brantsaeter AL, Meltzer HM, Alexander J, et al. Determinants of plasma PCB, brominated flame retardants, and organochlorine pesticides in pregnant women and 3 year old children in the Norwegian mother and child cohort study. Environ Res. 2016;146:136–44.
Dalsager L, Fage-Larsen B, Bilenberg N, Jensen TK, Nielsen F, Kyhl HB, et al. Maternal urinary concentrations of pyrethroid and chlorpyrifos metabolites and attention deficit hyperactivity disorder (ADHD) symptoms in 2-4-year-old children from the Odense Child Cohort. Environ Res. 2019;176: 108533.
Viel J-F, Rouget F, Warembourg C, Monfort C, Limon G, Cordier S, Chevrier C. Behavioural disorders in 6-year-old children and pyrethroid insecticide exposure: the PELAGIE mother-child cohort. Occup Environ Med. 2017;74(4):275–81.
Kirkeleit J, Riise T, Bjorge T, Christiani DC, Bratveit M, Baccarelli A, et al. Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian mother and child cohort study. Br J Cancer. 2018;119(8):1028–35.
Villanueva CM, Gracia-Lavedan E, Julvez J, Santa-Marina L, Lertxundi N, Ibarluzea J, et al. Drinking water disinfection by-products during pregnancy and child neuropsychological development in the INMA Spanish cohort study. Environ Int. 2018;110:113–22.
Castorina R, Bradman A, Stapleton HM, Butt C, Avery D, Harley KG, et al. Current-use flame retardants: maternal exposure and neurodevelopment in children of the CHAMACOS cohort. Chemosphere. 2017;189:574–80.
Impinen A, Longnecker MP, Nygaard UC, London SJ, Ferguson KK, Haug LS, Granum B. Maternal levels of perfluoroalkyl substances (PFASs) during pregnancy and childhood allergy and asthma related outcomes and infections in the Norwegian Mother and Child (MoBa) cohort. Environ Int. 2019;124:462–72.
Sol CM, Santos S, Asimakopoulos AG, Martinez-Moral M-P, Duijts L, Kannan K, et al. Associations of maternal phthalate and bisphenol urine concentrations during pregnancy with childhood blood pressure in a population-based prospective cohort study. Environ Int. 2020;138: 105677.
Chan KL, Brownridge DA, Fong DYT, Tiwari A, Leung WC, Ho PC. Violence against pregnant women can increase the risk of child abuse: a longitudinal study. Child Abuse Negl. 2012;36(4):275–84.
Conway LJ, Cook F, Cahir P, Brown S, Reilly S, Gartland D, et al. Children’s language abilities at age 10 and exposure to intimate partner violence in early childhood: results of an Australian prospective pregnancy cohort study. Child Abuse Negl. 2021;111: 104794.
Salazar M, Hogberg U, Valladares E, Persson L-A. Intimate partner violence and early child growth: a community-based cohort study in Nicaragua. BMC Pediatr. 2012;12: 82.
Whitehouse AJ, Robinson M, Zubrick SR, Ang Q, Stanley FJ, Pennell CE. Maternal life events during pregnancy and offspring language ability in middle childhood: the Western Australian Pregnancy Cohort Study. Early Hum Dev. 2010;86(8):487–92.
Norwegian Institute of Public Health. Access to data and biological material from the Norwegian Mother, Father and Child Cohort Study (MoBa) [updated 08.03.2023. Available from: https://www.fhi.no/en/studies/moba/for-forskere-artikler/research-and-data-access/.
Kjøbli E, Bach R, Skogseth H, Jacobsen GW. The Scandinavian Small-for-Gestational Age (SGA) pregnancy and birth cohort–a source to continual insight into fetal growth restriction and long term physical and neurodevelopmental health in mother and offspring. Norsk Epidemiologi. 2016;26(1–2).
Berkeley CERCH [Available from: https://cerch.berkeley.edu/investigators.
Tan J, Xiong YQ, He Q, Liu YM, Wang W, Chen M, et al. Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2019;19(1):302.
Mahmassani HA, Switkowski KM, Scott TM, Johnson EJ, Rifas-Shiman SL, Oken E, Jacques PF. Maternal intake of lutein and zeaxanthin during pregnancy is positively associated with offspring verbal intelligence and behavior regulation in mid-childhood in the project viva cohort. J Nutr. 2021;151(3):615–27.
Sontag-Padilla L, Burns RM, Shih RA, Griffin BA, Martin LT, Chandra A, Tylavsky F. The urban child institute CANDLE study. Santa Monica, CA: RAND Corporation; 2015.
Hyde NK, Brennan-Olsen SL, Wark JD, Hosking SM, Vuillermin PJ, Williams LJ, Pasco JA. The vitamin D in pregnancy study: a prospective prebirth cohort in southern Australia. BMJ Open. 2020;10(8): e036003.
Qiao L, Martelli CMT, Raja AI, Clemente NS, de Araùjo TVB, de Alencar Ximenes RA, et al. Epidemic preparedness: Prenatal Zika virus screening during the next epidemic. BMJ Glob Health. 2021;6(6): e005332.
de Vasconcelos ZFM, Azevedo RC, Thompson N, Gomes L, Guida L, Moreira MEL. Challenges for molecular and serological ZIKV infection confirmation. Childs Nerv Syst. 2018;34:79–84.
Health Inequalities and Infectious Disease Epidemics. A Challenge for Global Health Security. Biosecur Bioterror. 2014;12(5):263–73.
Lim SS, Mokdad AH. Socioeconomic inequalities and infectious disease burden. Lancet. 2012;379(9821):1080–1.
Wu M, Seel M, Britton S, Dean JA, Lazarou M, Safa H, et al. Addressing the crisis of congenital syphilis: key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South-East Queensland. Aust N Z J Obstet Gynaecol. 2022;62(1):91–7.
Brasil P, Pereira JPJ, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016;375(24):2321–34.
Wicher V, Wicher K. Pathogenesis of maternal-fetal syphilis revisited. Clin Infect Dis. 2001;33(3):354–63.
Carles G, Lochet S, Youssef M, El Guindi W, Helou G, Alassas N, Lambert V. Syphilis and pregnancy. J Gynecol Obstet Biol Reprod. 2007;37(4):353–7.
Gomez GB, Kamb ML, Newman LM, Mark J, Broutet N, Hawkes SJ. Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. Bull World Health Organ. 2013;91(3):217–26.
Coyne CB, Lazear HM. Zika virus — reigniting the TORCH. Nat Rev Microbiol. 2016;14(11):707–15.
Ornoy A, Ergaz Z. Parvovirus B19 infection during pregnancy and risks to the fetus. Birth Defects Res. 2017;109(5):311–23.
Xiong YQ, Tan J, Liu YM, He Q, Li L, Zou K, Sun X. The risk of maternal parvovirus B19 infection during pregnancy on fetal loss and fetal hydrops: a systematic review and meta-analysis. J Clin Virol. 2019;114:12–20.
Scheller NM, Pasternak B, Mølgaard-Nielsen D, Svanström H, Hviid A. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes. N Engl J Med. 2017;376(13):1223–33.
López-Fauqued M, Zima J, Angelo MG, Stegmann JU. Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccine. Vaccine. 2017;35(40):5325–30.
Badell ML, Meaney-Delman D, Tuuli MG, Rasmussen SA, Petersen BW, Sheffield JS, et al. Risks associated with smallpox vaccination in pregnancy: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(6):1439–51.
McMillan M, Clarke M, Parrella A, Fell DB, Amirthalingam G, Marshall HS. Safety of tetanus, diphtheria, and pertussis vaccination during pregnancy: a systematic review. Obstet Gynecol. 2017;129(3):560–73.
McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. Vaccine. 2015;33(18):2108–17.
Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf. 2017;16(10):1181–90.
Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women? Pharmacoepidemiol Drug Saf. 2016;25(7):770–7.
Bergeron J, Doiron D, Marcon Y, Ferretti V, Fortier I. Fostering population-based cohort data discovery: the Maelstrom Research cataloguing toolkit. PLoS ONE. 2018;13(7): e0200926.
Myatt L, Roberts JM, Redman CWG. Availability of COLLECT, a database for pregnancy and placental research studies worldwide. Placenta. 2017;57:223–4.
© 2025. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.